Table 1. Correlation of Fli-1 expression with clinicopathologic parameters in patients with astrocytoma.
| No. of patients | Fli-1 expression (n, %) | P-value | ||
|---|---|---|---|---|
| Low | High | |||
| Age (years) | 0.801 | |||
| >60 | 27 | 6 (5.6%) | 21 (19.4%) | |
| ≤60 | 81 | 22 (20.4%) | 59 (54.6%) | |
| Sex | 1 | |||
| Male | 61 | 16 (14.8%) | 45 (41.7%) | |
| Female | 47 | 12 (11.1%) | 35 (32.4%) | |
| WHO Grade | <0.001 | |||
| II | 28 | 18 (16.7%) | 10 (9.3%) | |
| III/IV | 80 | 10 (9.3%) | 70 (64.8%) | |
| Tumor size | 0651 | |||
| ≤3cm | 68 | 19 (17.6%) | 49 (45.4%) | |
| >3cm | 40 | 9 (8.3%) | 31 (28.7%) | |
| KPS | 0.159 | |||
| ≤70 | 74 | 16 (14.8%) | 58 (53.7%) | |
| >70 | 34 | 12 (11.1%) | 22 (20.4%) | |
*Statistical significance (P < 0.05).
WHO, World Health Organization; KPS, Karnofsky performance score.